Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer harboring mutations in MET exon 14. It helps patients control the spread of pathological cells by i···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：268
Exkivity reduces the growth of non-small cell lung cancer by binding to and inhibiting EGFR exon 20 insertion mutations.What interactions can occur with other medicationsExkivity m···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：237
Exkivity works by binding to and blocking EGFR exon 20 insertion mutations, which helps to slow the growth of cancer cells.Which drugs interact with ExkivityExkivity may interact w···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：268
Exkivity was granted accelerated FDA approval in 2021 based on results from the clinical trial NCT02716116. It is used with the Oncomine Dx Target Test, which identifies patients w···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：287
Exkivity capsules can be used by adults with non-small cell lung cancer that has spread to other parts of the body (metastatic) and cannot be removed with surgery, whose disease ha···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：203
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation.What does Mobotinib pay attenti···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：233
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation. Exkivity reduces the growth of···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：222
Capmatinib targets the activity of MET receptors and blocks the tumor cell growth signaling pathway driven by MET receptors, enabling effective treatment for patients with non-smal···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：269
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-competitive properties, which can significantly inhibit the proliferation and migration ability of c-Met···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：259
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosine kinase, making it particularly suitable for lung cancer patients with MET14 exon skipping mutation···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：259
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and blocking the proliferation and migration of tumor cells. Exkivityhas been approved by the United States ···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：225
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor activity, especially for the treatment of c-Met-dependent tumors.What are the side effects that can occ···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：252
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
